Shaun Chilton – CEO, Clinigen Group, UK
A British success story, Clinigen Group provides companies with services in portfolio and product lifecycle management on a global basis. Its CEO, Shaun Chilton, talks to us about the value…
The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care.
NICE was originally set up in 1999 as the National Institute for Clinical Excellence, a special health authority, to reduce variation in the availability and quality of NHS treatments and care.
In April 2013 we were established in primary legislation, becoming a Non Departmental Public Body (NDPB) and placing us on a solid statutory footing as set out in the Health and Social Care Act 2012. At this time we took on responsibility for developing guidance and quality standards in social care, and our name changed once more to reflect these new responsibilities.
As an NDPB, we are accountable to our sponsor department, the Department of Health and Social Care, but operationally we are independent of government.
The way NICE was established in legislation means that our guidance is officially England-only. However, we have agreements to provide certain NICE products and services to Wales, Scotland and Northern Ireland. Decisions on how our guidance applies in these countries are made by the devolved administrations, who are often involved and consulted with in the development of NICE guidance.
Contact:
Address: National Institute for Health and Care Excellence 10 Spring Gardens London SW1A 2BU
Tel.: +44 300 323 0140
Website: https://www.nice.org.uk/
Email: nice@nice.org.uk
A British success story, Clinigen Group provides companies with services in portfolio and product lifecycle management on a global basis. Its CEO, Shaun Chilton, talks to us about the value…
Having recently joined the UK operations of AstraZeneca after a varied international career, Laurent Abuaf shares his vision of the UK as a life sciences reference market and his take…
Heading Accord Healthcare’s European, Middle East and North African operations, James Burt highlights the rapid growth the company has achieved within the region and how it has reached an impressive…
Promoting the UK’s capital in times of Brexit, Laura Citron, CEO at London & Partners, the international promotional agency of the Mayor of London, stresses the critical importance life sciences…
Erik Nordkamp, managing director of Pfizer UK, has been confirmed as the new president of the Association of the British Pharmaceutical Industry (ABPI). With UK life sciences still uncertain as…
Craig Wallace established the UK affiliate of Santen, the Japanese ophthalmology company, in 2014. Wallace describes the journey Santen has been on so far in the UK, as well as…
Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by…
Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to ensure value creation, build on unique strengths and…
Having recently been able to present positive data for their lead technology IMCgp100 in uveal melanoma at the American Society of Clinical Oncology (ASCO), Immunocore looks at its future as…
Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains…
Stewart Pearce, managing director of Otsuka UK and Ireland since 2017 discloses how he built up a leadership team fit for the Otsuka of 2023 and highlights what he appreciates…
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
See our Cookie Privacy Policy Here